Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,... see more

GREY:ATBPF - Post Discussion

Antibe Therapeutics Inc(Pre-Merger) > Conference Call Tomorrow ...
View:
Post by MrMugsy on Jun 22, 2021 10:46pm

Conference Call Tomorrow ...

Raymond James tomorrow at 8:40 AM.

Based on the Bear Creek call today - sounds like a few things might be made a little clearer tomorrow (from what others are saying).

Someone remind Yukon not to take my advice ... he's too good to take that call anyway.

: )
Comment by themagicbox on Jun 23, 2021 9:18am
were you able to catch it any details? It just ended.
Comment by GameChangerBet on Jun 23, 2021 9:21am
No new material from what I heard. Although reassuring of all the material positives in the near-intermmediate term. 
Comment by MrMugsy on Jun 23, 2021 9:48am
Finished off the discussion with a reminder that OTENA peak sales of $4B is in reference to OA in 4 markets.  Looking at all indications ... OTENA is probably looking at $10B for peak.  If I understood that final comment.  Only had time for two questions
Comment by GameChangerBet on Jun 23, 2021 11:20am
All I know is that Otena has a very high probability of getting FDA approval and once that happens these guys will be generating million of dollars of free cash flow which will keep growing, month over month and year over year until peak sales.
Comment by JimmyJ on Jun 23, 2021 1:12pm
That's one option. Other alternatives could be: 1) License Otena to BP; 2) Sell Otena to BP;  3) Sell the company with all pipeline products, R&D, IP and resources to BP.  I'm hoping for a quick exit (option 3).
Comment by GameChangerBet on Jun 23, 2021 1:15pm
Yes absolutely. What I meant by generating cash flow is once the product hits the market, likely via a licensing deal. That's what they're targeting.  But yea without a doubt option 3 would be a great news release to wake up to
Comment by IrishCanuck on Jun 23, 2021 2:24pm
Something along the lines of "Dosing once daily with 150mg would cost payors $6.00 per day and with 98% profit margin, which is in line with typical pharmaceutical companies, it's shaping to be nice" got me FIIRREEEEDDDDD UPPPPPPP. Like YEA DAN THAT WOULD BE VERY NICE LOL
Comment by MrMugsy on Jun 23, 2021 2:50pm
Irish ...  agreed that the $6/day and high profit margin plays nicely during present partnering discussions. I also think the 150 mg was a separate thought from  Joe Stauffer indicating a confidence in that dose, with a chance for lower. Just the way I remember it - I might be wrong.
Comment by CalgaryATE on Jun 24, 2021 2:25am
After listening to it at my leisure tonight, the first question & answer was in regards to how were they planning on handling the placebo effect.  A little bit more detail on the 2nd question was: Q (29:00):  Total addressable market is far more significant beyond OA, plans for label expansion beyond OA?   A:  (29:30):  graph on investor deck ($4 billion US ...more  
Comment by MrMugsy on Jun 24, 2021 10:20am
And that's why we needed cash in the bank ... to buy time ... to have the ability to go into Phase 3 without Big Pharma giving us the gears to accept a less-than-optimal deal. I'd like to think we're driving this bus.  Slowly but surely, we'll get to our destination.  IMO.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities